tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 Mar 21;9(1):64.
doi: 10.1038/s41541-024-00857-5. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Man Xing[SUP] #[/SUP][SUP] 1 2 [/SUP], Gaowei Hu[SUP] #[/SUP][SUP] 3 [/SUP], Xiang Wang[SUP] #[/SUP][SUP] 2 [/SUP], Yihan Wang[SUP] #[/SUP][SUP] 1 [/SUP], Furong He[SUP] 1 [/SUP], Weiqian Dai[SUP] 1 [/SUP], Xinyu Wang[SUP] 4 [/SUP], Yixin Niu[SUP] 2 [/SUP], Jiaojiao Liu[SUP] 1 [/SUP], Hui Liu[SUP] 5 [/SUP], Xiaoyan Zhang[SUP] 2 [/SUP], Jianqing Xu[SUP] 6 [/SUP], Qiliang Cai[SUP] 7 [/SUP], Dongming Zhou[SUP] 8 9 [/SUP]
Affiliations
Despite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses continue to pose a severe global health burden. Thus, we developed a chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 and influenza virus. When used as a standalone vaccine, intranasal immunization with AdC68-HATRBD induced comprehensive and potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, and memory T cells, which protected the mice from BA.5.2 and pandemic H1N1 infections. When used as a heterologous booster, AdC68-HATRBD markedly improved the protective immune response of the licensed SARS-CoV-2 or influenza vaccine. Therefore, whether administered intranasally as a standalone or booster vaccine, this combination vaccine is a valuable strategy to enhance the overall vaccine efficacy by inducing robust systemic and mucosal immune responses, thereby conferring dual lines of immunological defenses for these two viruses.
. 2024 Mar 21;9(1):64.
doi: 10.1038/s41541-024-00857-5. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Man Xing[SUP] #[/SUP][SUP] 1 2 [/SUP], Gaowei Hu[SUP] #[/SUP][SUP] 3 [/SUP], Xiang Wang[SUP] #[/SUP][SUP] 2 [/SUP], Yihan Wang[SUP] #[/SUP][SUP] 1 [/SUP], Furong He[SUP] 1 [/SUP], Weiqian Dai[SUP] 1 [/SUP], Xinyu Wang[SUP] 4 [/SUP], Yixin Niu[SUP] 2 [/SUP], Jiaojiao Liu[SUP] 1 [/SUP], Hui Liu[SUP] 5 [/SUP], Xiaoyan Zhang[SUP] 2 [/SUP], Jianqing Xu[SUP] 6 [/SUP], Qiliang Cai[SUP] 7 [/SUP], Dongming Zhou[SUP] 8 9 [/SUP]
Affiliations
- PMID: 38509167
- DOI: 10.1038/s41541-024-00857-5
Despite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses continue to pose a severe global health burden. Thus, we developed a chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 and influenza virus. When used as a standalone vaccine, intranasal immunization with AdC68-HATRBD induced comprehensive and potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, and memory T cells, which protected the mice from BA.5.2 and pandemic H1N1 infections. When used as a heterologous booster, AdC68-HATRBD markedly improved the protective immune response of the licensed SARS-CoV-2 or influenza vaccine. Therefore, whether administered intranasally as a standalone or booster vaccine, this combination vaccine is a valuable strategy to enhance the overall vaccine efficacy by inducing robust systemic and mucosal immune responses, thereby conferring dual lines of immunological defenses for these two viruses.